AI Moves Deeper Into the Operating System of Drug Discovery
Six signals shaping AI × Cells
AI is now central enough to anchor major cancer-research forums
At AACR 2026, AI was prominent enough to anchor a plenary focused on the “AI revolution” across cancer labs and clinics, underlining how quickly AI has moved into the mainstream of cancer research and care.
Specialized life-science models are becoming real workflow tools
OpenAI’s GPT-Rosalind was launched as a life-sciences research model for biology, drug discovery, and translational medicine, with availability through ChatGPT, Codex, and the API for qualified users, plus a Codex plugin that connects to more than 50 scientific tools and data sources. This is a meaningful signal because it pushes AI closer to daily scientific work rather than general-purpose assistance alone.
Pharma is investing in AI as core R&D infrastructure
Boehringer Ingelheim’s new AI Accelerator in London shows that AI is being treated not just as an external capability, but as part of internal pharma research infrastructure. Reuters also reported the broader investment as £150 million over 10 years, reinforcing the scale of commitment.
AI–biopharma convergence is reaching the governance layer
Anthropic’s appointment of Novartis CEO Vas Narasimhan to its board is notable not only because of his life-sciences background, but because it brings biopharma perspective directly into the governance of a frontier AI company. That is a different kind of signal from a partnership or pilot.
Lab-in-the-loop platforms keep getting more concrete
Eclipsebio’s eCOMPASS platform is directly relevant to the AI × Cells conversation because it combines AI-enabled design, rapid prototyping, and sequencing-based characterization in a lab-in-the-loop workflow for RNA therapeutics. This is exactly the kind of signal that shows how AI becomes more useful when it is tied to iterative experimental feedback.
Hyperscalers are building discovery-native AI layers
AWS’s Amazon Bio Discovery brings together biological foundation models, an AI assistant for workflow orchestration, and integrated lab testing partners, making design-test-learn cycles easier to run. Reuters reported that the platform is aimed at early-stage drug discovery and already has early users including Bayer, the Broad Institute, and Voyager Therapeutics.